Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 14.08.2025 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Inter |
| 20.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | nnual Meeting, and all as previously disclosed in Item 5.02 of the Current Report on Form 8-K filed on November 19, 2024 |
| 14.11.2024 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | Item 4.02, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Inter |
| 16.04.2024 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | reet NE Washington, DC 20549 We have read Item 4.02 of Form 8-K dated April 11, 2024 of Conduit Pharmaceuticals Inc. a |
Stammdaten
CDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.
Unternehmen & Branche
| Name | CDT Equity Inc. |
|---|---|
| Ticker | CDT |
| CIK | 0001896212 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 394.351 USD |
| Beta | 2,08 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -39,224,000 | -###.## | 5,650,000 | -7,170,000 | |
| 2025-09-30 | 10-Q | -7,118,000 | -13.16 | 8,552,000 | 4,278,000 | |
| 2025-06-30 | 10-Q | -6,028,000 | -5.46 | 7,989,000 | 3,529,000 | |
| 2025-03-31 | 10-Q | -5,146,000 | -1.32 | 7,321,000 | 3,080,000 | |
| 2024-12-31 | 10-K | -17,802,000 | -###.## | 4,193,000 | -6,793,000 | |
| 2024-09-30 | 10-Q | -6,461,000 | -889.58 | 2,993,000 | -9,118,000 | |
| 2024-06-30 | 10-Q | -5,383,000 | -109.33 | 3,305,000 | -5,462,000 | |
| 2024-03-31 | 10-Q | -3,552,000 | -4.81 | 4,917,000 | -3,098,000 | |
| 2023-12-31 | 10-K | -535,000 | -8.92 | 7,224,000 | -457,000 | |
| 2023-09-30 | 10-K | 2,625,000 | 0.01 | |||
| 2023-09-30 | 10-Q | 2,625,000 | 0.01 | 12,018,000 | -1,081,000 | |
| 2023-06-30 | 10-K | -2,106,000 | -###.## | 900,000 | -14,513,000 | |
| 2023-06-30 | 10-Q | -2,106,000 | -0.03 | 900,000 | -14,140,000 | |
| 2023-03-31 | 10-K | -1,672,000 | -835.00 | 506,000 | -12,024,000 | |
| 2023-03-31 | 10-Q | -1,672,000 | -0.03 | 506,000 | -12,024,000 | |
| 2022-12-31 | 10-K | -4,887,000 | -0.13 | 5,000 | -10,089,000 | |
| 2022-09-30 | 10-Q | -956,000 | -0.03 | 136,853,167 | -6,489,000 | |
| 2022-06-30 | 10-Q | -117,539 | 136,468,779 | -6,141,000 | ||
| 2022-03-31 | 10-Q | -253,536 | 136,526,029 | -3,076,078 | ||
| 2021-12-31 | 10-K | -4,381 | 213,125 | -5,955,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.